WO2005004854A3 - Utilisation de la betaine pour le traitement des arterites - Google Patents

Utilisation de la betaine pour le traitement des arterites Download PDF

Info

Publication number
WO2005004854A3
WO2005004854A3 PCT/BE2004/000101 BE2004000101W WO2005004854A3 WO 2005004854 A3 WO2005004854 A3 WO 2005004854A3 BE 2004000101 W BE2004000101 W BE 2004000101W WO 2005004854 A3 WO2005004854 A3 WO 2005004854A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
arteritis
betaine
describes
intermittent claudication
Prior art date
Application number
PCT/BE2004/000101
Other languages
English (en)
Other versions
WO2005004854A2 (fr
Inventor
Jallal Messadek
Original Assignee
Jallal Messadek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jallal Messadek filed Critical Jallal Messadek
Priority to DE602004031631T priority Critical patent/DE602004031631D1/de
Priority to EP04737684A priority patent/EP1656131B1/fr
Priority to CA002569537A priority patent/CA2569537A1/fr
Priority to DK04737684.3T priority patent/DK1656131T3/da
Priority to AT04737684T priority patent/ATE499933T1/de
Priority to PL04737684T priority patent/PL1656131T3/pl
Publication of WO2005004854A2 publication Critical patent/WO2005004854A2/fr
Publication of WO2005004854A3 publication Critical patent/WO2005004854A3/fr
Priority to US11/333,514 priority patent/US20060160896A1/en
Priority to US12/726,109 priority patent/US8343947B2/en
Priority to US13/709,833 priority patent/US20130096195A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

La présente invention décrit l’utilisation de la bétaine pour le traitement et la prévention des artérites. La présente invention décrit également une composition à usage oral pour le traitement des artérites et en particulier de la claudication intermittente, ladite composition comprenant comme principe actif unique une quantité thérapeutiquement active de glycine bétaine par dose unitaire. Plus particulièrement l’invention décrit un médicament destiné à traiter un malade souffrant d’une claudication intermittente causée par des désordres circulatoires périphériques tels que l’artériosclérose oblitérante ou la thrombo-angéite oblitérante.
PCT/BE2004/000101 2002-02-04 2004-07-08 Utilisation de la betaine pour le traitement des arterites WO2005004854A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE602004031631T DE602004031631D1 (de) 2003-07-15 2004-07-08 Verwendung von betain zur behandlung von claudicatio intermittens
EP04737684A EP1656131B1 (fr) 2003-07-15 2004-07-08 Utilisation de la betaine pour le traitement de la claudication intermittente
CA002569537A CA2569537A1 (fr) 2003-07-15 2004-07-08 Utilisation de la betaine pour le traitement des arterites
DK04737684.3T DK1656131T3 (da) 2003-07-15 2004-07-08 Anvendelse af betain til behandling claudicatio intermittens
AT04737684T ATE499933T1 (de) 2003-07-15 2004-07-08 Verwendung von betain zur behandlung von claudicatio intermittens
PL04737684T PL1656131T3 (pl) 2003-07-15 2004-07-08 Zastosowanie betainy w leczeniu chromania przestankowego
US11/333,514 US20060160896A1 (en) 2002-02-04 2006-01-17 Therapeutic treatment
US12/726,109 US8343947B2 (en) 2003-07-15 2010-03-17 Therapeutic treatment
US13/709,833 US20130096195A1 (en) 2003-07-15 2012-12-10 Therapeutic treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE2003/0408A BE1015608A6 (fr) 2003-07-15 2003-07-15 Traitement des arterites.
BE2003/0408 2003-07-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/333,514 Continuation-In-Part US20060160896A1 (en) 2002-02-04 2006-01-17 Therapeutic treatment

Publications (2)

Publication Number Publication Date
WO2005004854A2 WO2005004854A2 (fr) 2005-01-20
WO2005004854A3 true WO2005004854A3 (fr) 2005-06-16

Family

ID=33569382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2004/000101 WO2005004854A2 (fr) 2002-02-04 2004-07-08 Utilisation de la betaine pour le traitement des arterites

Country Status (11)

Country Link
US (2) US8343947B2 (fr)
EP (1) EP1656131B1 (fr)
AT (1) ATE499933T1 (fr)
BE (1) BE1015608A6 (fr)
CA (1) CA2569537A1 (fr)
DE (1) DE602004031631D1 (fr)
DK (1) DK1656131T3 (fr)
ES (1) ES2361915T3 (fr)
PL (1) PL1656131T3 (fr)
PT (1) PT1656131E (fr)
WO (1) WO2005004854A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2523412C1 (ru) * 2013-02-25 2014-07-20 Общество с ограниченной ответственностью "МЕЖДУНАРОДНЫЙ ЦЕНТР КЛИНИЧЕСКОЙ ЛИМФОЛОГИИ" Способ лечения больных облитерирующими заболеваниям и артерий нижних конечностей

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1013958A6 (fr) * 2001-02-05 2003-01-14 Messadek Jallal Antagonistes glycoproteiques.
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
WO2006050581A2 (fr) 2004-11-10 2006-05-18 Jallal Messadek Betaine en tant qu'agent de lutte contre des maladies transmises par des arthropodes ou des moustiques
WO2006086856A1 (fr) 2005-02-15 2006-08-24 Messadek, Jallal Compositions therapeutiques combinees et leurs procedes d’utilisation
EP1853544A4 (fr) 2005-02-24 2010-06-16 Diffusion Pharmaceuticals Llc Transcarotenoides et leur synthese, leur preparation et leurs utilisations
CN101180073A (zh) 2005-04-27 2008-05-14 贾拉尔·梅萨德克 胰岛素组合
US8206751B2 (en) * 2007-10-31 2012-06-26 Diffusion Pharmaceuticals Llc Class of therapeutics that enhance small molecule diffusion
WO2009065193A1 (fr) * 2007-11-21 2009-05-28 Jallal Messadek Traitement de la résistance à l'aspirine par de la bétaïne et/ou de la mélasse enrichie en bétaïne
EP2445339B1 (fr) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Composé améliorant la diffusion et son utilisation avec un thrombolytique
ES2654945T3 (es) 2010-06-02 2018-02-15 Diffusion Pharmaceuticals Llc Formulaciones orales de carotenoides trans bipolares
CN109152839A (zh) 2016-03-24 2019-01-04 扩散药品有限公司 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2119889A1 (en) * 1970-12-31 1972-08-11 Vegetti Tiberio Deoxyribonucleic acid compsns - for treating degenerating mesenchyma,parenchyma or arteriosclerosis
WO1995015750A1 (fr) * 1993-12-10 1995-06-15 Hashim Sami A Reduction de la probabilite d'apparition de troubles vasculaires chez des sujets a risque
US5716941A (en) * 1993-07-07 1998-02-10 Biogenesys Use of methyl donor compounds to treat neurological dysfunction associated with immune defects
WO1998019690A1 (fr) * 1996-11-06 1998-05-14 Bristol-Myers Squibb Company Methode de traitement de la maladie d'alzheimer
WO2000025764A2 (fr) * 1998-10-30 2000-05-11 Merck Patent Gmbh Compositions de traitement et de prevention de maladies cardio-vasculaires
WO2002062322A2 (fr) * 2001-02-05 2002-08-15 Jallal Messadek Glycine-betaine et utilisation correspondante
US20020183380A1 (en) * 1996-12-02 2002-12-05 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
WO2004049095A2 (fr) * 2002-11-25 2004-06-10 Jallal Messadek Compositions de betaine

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE644568C (de) * 1934-04-19 1937-05-07 Bristol Aeroplane Co Ltd Kopierfraesmaschine
FR2590M (fr) 1963-03-12 1964-06-15 Albert Beaufour Nouvelles associations antinévralgiques a tolérance améliorée.
US3577534A (en) 1968-06-20 1971-05-04 Canada Packers Ltd Stable orally active heparinoid complexes
GB1509979A (en) 1975-11-28 1978-05-10 Fisons Ltd Pharmaceutical compositions containing aspirin or indomethacin
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
FR2403799A2 (fr) 1977-09-27 1979-04-20 Union Pharma Scient Appl Solution d'acide acetylsalicylique extemporanee injectable
US4605548A (en) 1983-05-31 1986-08-12 Nitto Electric Industrial Co., Ltd. Drug administration material
GB8325627D0 (en) 1983-09-24 1983-10-26 Scras Therapeutic compositions
DK162986A (da) 1985-04-12 1986-10-13 Forest Laboratories Terapeutisk middel i enhedsdosisform
AU607172B2 (en) 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
HU210122B (en) 1988-03-23 1995-02-28 Biorex Kutato Fejlesztoe Kft Process for production of composition against thromboembolytic conditions of circulating system and heart
US4902718A (en) 1988-04-08 1990-02-20 Bayless Robert K Calcium homeostasis compositions and methods for controlling calcium metabolism
EP0347864A3 (fr) 1988-06-24 1992-04-01 Andries Johannes Cornelus Strydom Agents antiathérogéniques
IT1226386B (it) 1988-07-08 1991-01-15 Chiesi Farma Spa Procedimento di preparazione di morniflumato e analoghi.
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
EP0441119A3 (en) 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5405614A (en) 1992-04-08 1995-04-11 International Medical Associates, Inc. Electronic transdermal drug delivery system
US5342621A (en) 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US5876780A (en) 1993-04-29 1999-03-02 Cultor, Ltd. Compositions for treating coccidiosis
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US6355166B1 (en) 1994-08-25 2002-03-12 The University Of Iowa Research Foundation Magnetically enhanced composite materials and methods for making and using the same
US6056958A (en) 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
US5961999A (en) 1995-06-08 1999-10-05 Wella Aktiengesellschaft Method of skin care using a skin care preparation containing a betaine ester and an α-hydroxy acid
JP3119430B2 (ja) 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
US6162926A (en) 1995-07-31 2000-12-19 Sphere Biosystems, Inc. Multi-substituted fullerenes and methods for their preparation and characterization
LV11727B (en) 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
US7045585B2 (en) 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
WO1997027829A1 (fr) 1996-01-31 1997-08-07 The Trustees Of The University Of Pennsylvania Dispositif d'administration de medicament commande a distance
US5688499A (en) 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
SE9601396D0 (sv) 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 2
US5880098A (en) 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
SE9601395D0 (sv) 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US6258859B1 (en) 1997-06-10 2001-07-10 Rhodia, Inc. Viscoelastic surfactant fluids and related methods of use
EP1061908A4 (fr) 1998-03-13 2007-01-24 Merck & Co Inc Therapie associee destinee au syndrome ischemique coronarien aigu ainsi qu'a des troubles connexes
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
RU2219924C2 (ru) 1998-04-14 2003-12-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения нейропсихиатрических расстройств
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
JP2000143486A (ja) 1998-11-12 2000-05-23 Lion Corp 皮膚外用剤
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
BE1013958A6 (fr) 2001-02-05 2003-01-14 Messadek Jallal Antagonistes glycoproteiques.
BE1012495A3 (fr) 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
DE19910682B4 (de) 1999-03-10 2004-09-02 Dierkes, Jutta, Dr. Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie
BE1012546A6 (fr) 1999-03-10 2000-12-05 Messadek Jallal La betaine et ses derives pour leur usage antithrombotique.
BE1012712A6 (fr) 1999-06-10 2001-02-06 Messadek Jallal Peptides antithrombotiques.
DE10004651A1 (de) 2000-02-03 2001-08-16 Jutta Dierkes Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen
CN1313080C (zh) * 2000-04-20 2007-05-02 斯凯伊药品加拿大公司 改进的水不溶性药物粒子的制备方法
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
EP1305021A4 (fr) 2000-06-23 2009-09-23 Teva Pharma Composition a expansion rapide pour retention gastrique et liberation regulee d'agents therapeutiques, et formes posologiques renfermant cette composition
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
FR2811227A1 (fr) 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
DE10038539A1 (de) 2000-08-03 2002-02-21 Bosch Gmbh Robert Verfahren und Vorrichtung zur energiesparenden Dichtheitsprüfung einer Brennstofftankanlage insbesondere eines Kraftfahrzeuges
US6624180B2 (en) 2000-11-20 2003-09-23 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
WO2002047493A2 (fr) 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Compositions de composes destinees a la promotion de la sante
FI114538B (fi) 2001-01-12 2004-11-15 Finnfeeds Finland Ltd Glysiinibetaiinin käyttö verenpainetta alentavan tuotteen valmistukseen
AU2002257582A1 (en) 2001-02-14 2002-09-04 Glaxo Wellcome S.A. Pharmaceutical formulation
US20040072750A1 (en) 2001-05-03 2004-04-15 David Phillips Compounds and methods for the modulation of CD154
US6531171B2 (en) 2001-07-03 2003-03-11 Nutricia Usa, Inc. Food products containing betaine
WO2003020260A1 (fr) 2001-08-31 2003-03-13 Metaproteomics, Llc Composition d'arginine pour une modification coordonnee de facteurs de risque cardio-vasculaire multiples
US20030170223A1 (en) 2002-02-01 2003-09-11 Board Of Trustees Of Michigan State University Pulmonary vasodilator surfactant compositions and method of use
US20060160896A1 (en) 2002-02-04 2006-07-20 Jallal Messadek Therapeutic treatment
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
EP1518120A4 (fr) 2002-03-11 2008-08-13 Momenta Pharmaceuticals Inc Analyse de polysaccharides sulfates
TW200307551A (en) 2002-04-16 2003-12-16 Tanabe Seiyaku Co Phenol compound, process for preparing the same and synthetic intermediate thereof
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040067986A1 (en) 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
WO2004091601A1 (fr) 2003-04-17 2004-10-28 Jallal Messadek Formulations orales flottantes pour la liberation controlee de la betaine
DE10319376B4 (de) 2003-04-30 2007-01-04 Uponor Innovation Ab Pressbacke für ein Presswerkzeug zum Verpressen von Fittingen, Presswerkzeug und Werkzeug zum axialen Aufschieben einer Hülse
US7097968B2 (en) 2003-07-10 2006-08-29 General Atomics Methods and compositions for assaying homocysteine
US20060128657A1 (en) 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
WO2005011645A2 (fr) 2003-08-04 2005-02-10 Jallal Messadek Betaines specifiques et leurs utilisations
EP1663174A1 (fr) 2003-08-05 2006-06-07 Galephar M/F Composition pharmaceutique a unite simple comprenant un melange de fibranne et un agent reducteur d'homocysteine
WO2005065675A1 (fr) 2004-01-07 2005-07-21 Premacs International Pty. Ltd. Methode de traitement
BRPI0510167A (pt) 2004-04-23 2007-10-02 Celgene Corp método para tratar, prevenir ou controlar hipertensão pulmonar
BE1016128A6 (fr) 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (fr) 2004-11-10 2006-05-18 Jallal Messadek Betaine en tant qu'agent de lutte contre des maladies transmises par des arthropodes ou des moustiques
WO2006086856A1 (fr) 2005-02-15 2006-08-24 Messadek, Jallal Compositions therapeutiques combinees et leurs procedes d’utilisation
CN101180073A (zh) 2005-04-27 2008-05-14 贾拉尔·梅萨德克 胰岛素组合

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2119889A1 (en) * 1970-12-31 1972-08-11 Vegetti Tiberio Deoxyribonucleic acid compsns - for treating degenerating mesenchyma,parenchyma or arteriosclerosis
US5716941A (en) * 1993-07-07 1998-02-10 Biogenesys Use of methyl donor compounds to treat neurological dysfunction associated with immune defects
WO1995015750A1 (fr) * 1993-12-10 1995-06-15 Hashim Sami A Reduction de la probabilite d'apparition de troubles vasculaires chez des sujets a risque
WO1998019690A1 (fr) * 1996-11-06 1998-05-14 Bristol-Myers Squibb Company Methode de traitement de la maladie d'alzheimer
US20020183380A1 (en) * 1996-12-02 2002-12-05 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
WO2000025764A2 (fr) * 1998-10-30 2000-05-11 Merck Patent Gmbh Compositions de traitement et de prevention de maladies cardio-vasculaires
WO2002062322A2 (fr) * 2001-02-05 2002-08-15 Jallal Messadek Glycine-betaine et utilisation correspondante
WO2004049095A2 (fr) * 2002-11-25 2004-06-10 Jallal Messadek Compositions de betaine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"BETAINE FOR HOMOCYSTINURIA", MEDICAL LETTER ON DRUGS AND THERAPEUTICS, NEW ROCHELLE, NY, US, vol. 39, no. 993, 31 January 1997 (1997-01-31), pages 12, XP000853853, ISSN: 0025-732X *
AL-AWAMI M ET AL: "Homocysteine levels in patients with Raynaud's phenomenon", VASA - JOURNAL OF VASCULAR DISEASES 2002 SWITZERLAND, vol. 31, no. 2, 2002, pages 87 - 90, XP008039171, ISSN: 0301-1526 *
DIDIER A -F ET AL: "Distal cutaneous necrosis, an unusual etiology: Hyperhomocysteinemia", ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, vol. 126, no. 11, November 1999 (1999-11-01), pages 822 - 825, XP008039169, ISSN: 0151-9638 *
MALINOW M R (REPRINT): "PLASMA HOMOCYST(E)INE AND ARTERIAL OCCLUSIVE DISEASES - A MINIREVIEW", CLINICAL CHEMISTRY, (JAN 1995) VOL. 41, NO. 1, PP. 173-176. ISSN: 0009-9147., January 1995 (1995-01-01), XP008039186 *
STAMMLER F ET AL: "Prevalence of hyperhomocysteinaemia in thrombangiitis obliterans (Buerger's disease): Does homocysteine play a pathogenetic role?", DMW (DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT), vol. 121, no. 46, 1996, pages 1417 - 1423, XP008039176, ISSN: 0012-0472 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2523412C1 (ru) * 2013-02-25 2014-07-20 Общество с ограниченной ответственностью "МЕЖДУНАРОДНЫЙ ЦЕНТР КЛИНИЧЕСКОЙ ЛИМФОЛОГИИ" Способ лечения больных облитерирующими заболеваниям и артерий нижних конечностей

Also Published As

Publication number Publication date
DE602004031631D1 (de) 2011-04-14
BE1015608A6 (fr) 2005-06-07
US8343947B2 (en) 2013-01-01
US20130096195A1 (en) 2013-04-18
DK1656131T3 (da) 2011-06-14
ES2361915T3 (es) 2011-06-24
PT1656131E (pt) 2011-06-07
ATE499933T1 (de) 2011-03-15
CA2569537A1 (fr) 2005-01-20
EP1656131A2 (fr) 2006-05-17
WO2005004854A2 (fr) 2005-01-20
PL1656131T3 (pl) 2011-07-29
US20100210608A1 (en) 2010-08-19
EP1656131B1 (fr) 2011-03-02

Similar Documents

Publication Publication Date Title
WO2004073614A3 (fr) Polytherapie servant au traitement de troubles immuno-inflammatoires
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2004009558A3 (fr) Composes d'acide benzoique a substitution ureido et leur utilisation pour la suppression de non-sens et le traitement de maladie
EP1558220A4 (fr) Compositions orales pour le traitement de maladies
WO2002100390A3 (fr) Methode amelioree de traitement du syndrome des facteurs de risque de coronaropathie chez l'etre humain
WO2005067546A3 (fr) Derives et analogues de pyrrolopyrimidine et utilisation de ceux-ci dans le traitement a la prevention de maladies
WO2004043341A3 (fr) Traitement pour choc hémorragique
EP1938814A4 (fr) Produit pharmaceutique destine a proteger un nerf moteur chez les patients atteints de sclerose laterale amyotrophique
WO2004103297A3 (fr) Polytherapie a base d'acetate de glatiramer et de mitoxantrone destinee au traitement de la sclerose en plaques
WO2005004854A3 (fr) Utilisation de la betaine pour le traitement des arterites
TW200616644A (en) Medicine for prevention or treatment of diabetes
WO2004110380A3 (fr) Traitement des maladies a mediation immunologique au moyen de composes a base de vitamine d active, seuls ou en association avec d'autres agents therapeutiques
WO2006002096A3 (fr) Faibles doses de l-citrulline pour traiter des maladies
EP1637132A4 (fr) Preparation externe permettant de traiter les pieds d'un athlete
WO2005082413A3 (fr) Combinaison de ciclesonide et de glycopyrronium
WO1999040883A3 (fr) Compositions et techniques de traitement de la mucoviscidose
HK1081861A1 (en) New synergistic combination comprising roflumilast and formoterol
WO2005092062A3 (fr) Composes destines aux troubles neurodegeneratifs
WO2004073615A3 (fr) Composes de deazaflavine et leurs methodes d'utilisation
MXPA02003484A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.
WO2004087880A3 (fr) Composes et leur utilisation dans le traitement du diabete et troubles connexes
WO2003018535A3 (fr) Nouvelles aminobenzophenones
SE0102887D0 (sv) New formulation
WO2005079767A3 (fr) Moyen de modulation des effets de substances de type opioide
TW200608965A (en) Medicine for prevention or treatment of diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11333514

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004737684

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004737684

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11333514

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2569537

Country of ref document: CA